Next-generation sequencing (NGS) of the original prostate tumor biopsy identified the presence of a somatic BRCA2 mutation, the patient’s germline PMS2 mutation, and 13.1 mutations/Mb tumor mutational burden (TMB). This evidence concerns the gene BRCA2 and prostate neoplasm.